company background image
CMXH.F logo

CSL OTCPK:CMXH.F Stock Report

Last Price

US$187.05

Market Cap

US$89.0b

7D

2.5%

1Y

-5.1%

Updated

29 May, 2024

Data

Company Financials +

CMXH.F Stock Overview

Researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally.

CMXH.F fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance4/6
Financial Health4/6
Dividends3/6

CSL Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for CSL
Historical stock prices
Current Share PriceAU$187.05
52 Week HighAU$207.67
52 Week LowAU$144.81
Beta0.30
1 Month Change6.19%
3 Month Change0.85%
1 Year Change-5.08%
3 Year Change-15.27%
5 Year Change34.09%
Change since IPO2,225.62%

Recent News & Updates

Recent updates

Shareholder Returns

CMXH.FUS BiotechsUS Market
7D2.5%-2.9%-0.6%
1Y-5.1%6.6%25.4%

Return vs Industry: CMXH.F underperformed the US Biotechs industry which returned 6.6% over the past year.

Return vs Market: CMXH.F underperformed the US Market which returned 25.4% over the past year.

Price Volatility

Is CMXH.F's price volatile compared to industry and market?
CMXH.F volatility
CMXH.F Average Weekly Movement4.4%
Biotechs Industry Average Movement11.0%
Market Average Movement5.9%
10% most volatile stocks in US Market15.9%
10% least volatile stocks in US Market2.9%

Stable Share Price: CMXH.F has not had significant price volatility in the past 3 months.

Volatility Over Time: CMXH.F's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
191632,065Paul McKenziewww.csl.com.au

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.

CSL Limited Fundamentals Summary

How do CSL's earnings and revenue compare to its market cap?
CMXH.F fundamental statistics
Market capUS$88.97b
Earnings (TTM)US$2.47b
Revenue (TTM)US$14.18b

36.0x

P/E Ratio

6.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CMXH.F income statement (TTM)
RevenueUS$14.18b
Cost of RevenueUS$6.86b
Gross ProfitUS$7.32b
Other ExpensesUS$4.85b
EarningsUS$2.47b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Aug 13, 2024

Earnings per share (EPS)5.12
Gross Margin51.63%
Net Profit Margin17.43%
Debt/Equity Ratio54.4%

How did CMXH.F perform over the long term?

See historical performance and comparison

Dividends

1.3%

Current Dividend Yield

48%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.